Altria Group, Inc. · NYSE:MO
Altria — Consumer Analyst Group of New York (CAGNY) Conference 2020
59 slides from Altria's conference presentation, Feb 19, 2020
Slide 1: 2020 CAGNY Investor Presentation
2020 CAGNY Investor Presentation
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements, including earnings guidance, in this presentation that are not reported financial results or other historical information are “forward-looking statements” within the meaning of Private Securities Litigation Reform Act of 1995. Such forward-looking statements are bas
Slide 3: Tobacco Space Estimated Volume
Tobacco Space Estimated Volume Equivalized Volume in Billions Combustible Oral Tobacco E-Vapor (0.9%) 5yr CAGR 16.7 16.9 16.6 16.3 16.2 16.0 2014 2015 2016 2017 2018 2019 Sources: CMI Estimates; IRI MOC; Capstone; ComScore, Merkle EQ Estimation – For purposes of this theoretical analysis the followi
Slide 4: Adjusted Diluted Earnings Per Share Performance
Adjusted Diluted Earnings Per Share* Performance +10.4% CAGR $4.22 $2.57 2014 2019 * For reconciliation of non-GAAP to GAAP measures visit Altria.com Source: Altria company reports For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 4
Slide 5: Core Tobacco Business Operating Performance
Core Tobacco Business Operating Performance Smokeable and Smokeless Segments Smokeable and Smokeless Segments Combined Adjusted OCI* Combined Adjusted OCI* Margins +6.2% +10.1pp CAGR $10.8 B 56.5% $8.0 B 46.4% 2014 2019 2014 2019 * For reconciliation of non-GAAP to GAAP measures visit Altria.com Sou
Slide 6: Significant Cash Returns to Shareholders
Significant Cash Returns to Shareholders Cash Returned to Shareholders Dividends Per Share +10.1% $32 B CAGR $7 B $3.36 $2.08 $25 B 2015 - 2019 2014 2019 Dividends Paid Shares Repurchased Note: reported annualized dividend per share based on latest declared dividend For Investor Presentation ONLY |
Slide 7: Unmatched Noncombustible Brands & Investments
Unmatched Noncombustible Brands & Investments U.S. Smokeless Tobacco Co. IQOS & Copenhagen Exclusive license to the only Most profitable MST company FDA authorized heated with the # 1 brand tobacco system on! JUUL Broadest portfolio of oral Strategic investment in the nicotine pouches leading e-vapo
Slide 8: 10-Year Vision
10-YEAR VISION Responsibly lead the transition of adult smokers to a noncombustible future. For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 8
Slide 9: To Achieve Our Vision, We Will...
To Achieve Our Vision, We Will... Lead the industry in operating responsibly and preventing underage use of adult products. Develop and expand our portfolio of FDA-authorized, noncombustible products and actively convert adult smokers to them. Maximize the profitability of our combustible prod
Slide 10: Generational Lows in Youth Smoking Rates
Generational Lows in Youth Smoking Rates Monitoring The Future – 8th, 10th and 12th Grades Combined 30% 28.3% (87%) 3.7% 0% 1991 1994 1997 2000 2003 2006 2009 2012 2015 2018 Source: See detailed tables for 8th, 10th, 12th grades combined: http://www.monitoringthefuture.org/data/19data/19drtbl7.pdf F
Slide 11: We Must Earn Our License To Operate Every Day
We Must Earn Our License To Operate Every Day January 2019 Altria launches national campaign July 2019 Half of U.S. Population governed by Tobacco 21 state laws December 2019 Congress enacts federal Tobacco 21 legislation For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 11
Slide 12: Our Underage Tobacco Prevention Efforts
Our Underage Tobacco Prevention Efforts For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 12
Slide 13: Noncombustible Brands & Investments
Noncombustible Brands & Investments JUUL IQOS on! Strategic investment in the Exclusive license to the only FDA Broadest portfolio of leading e-vapor manufacturer authorized heated tobacco system oral nicotine pouches All-third party trademarks remain the property of their respective owners. For Inv
Slide 14: Path Forward for our JUUL Investment
Path Forward for our JUUL Investment We believe the recent agreement with JUUL better positions both companies for future success We continue to expect the FTC to complete its review in the first half of this year For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 14
Slide 15: Historical E-Vapor Category Performance
Historical E-Vapor Category Performance Estimated Equivalized Volume (in billions of units) JUUL Industry Balance 2.5 1.9 1.6 0.9 1.1 1.0 1.1 0.5 0.1 0.0 2015 2016 2017 2018 2019 Source: ALCS CMI estimates Volume equivalized to cartridges (1 disposable = 1 cartridge = 1mL e-liquid) Estimated categor
Slide 16: May 2020 PMTA Deadline for Newly Deemed Products
May 2020 PMTA Deadline for Newly Deemed Products In order to receive authorization, a manufacturer will have to submit significant scientific data to support that a product is appropriate for the protection of public health The PMTA standard is a high bar that we believe is warranted For Investo
Slide 17: We Believe The E-Vapor Category Needs:
We Believe The E-Vapor Category Needs: A market ultimately consisting solely of FDA authorized products Clear FDA marketing guidelines and ongoing post-market surveillance to help ensure that products do not reach unintended audiences Pro-active regulatory enforcement against noncompliant manu
Slide 18: 2019 National Youth Tobacco Survey Results
2019 National Youth Tobacco Survey Results Device type used most often among past 30-day Retail source of e-cigarettes among past 30 day high school and middle school e-cigarette users* high school and middle school e-cigarette users* ~37% 70% 35% 53.7% 17.5% 15.2% 24.2% 10.1% 9.4% 2.6% 0% 0% Pre-fi
Slide 19: U.S. Adult Smoker Experience With E-Vapor Products
U.S. Adult Smoker Experience With E-Vapor Products U.S. Adult Smokers Who Have Tried, We believe adult smokers are looking for But Rejected E-Vapor Products alternatives to cigarettes beyond just the e-vapor category 40% 40% of current U.S. adult smokers have tried, but ultimately rejected e-vap
Slide 20: All-third party trademarks remain the property of their respective owners. For Investor Presentation ONLY
All-third party trademarks remain the property of their respective owners. For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 20
Slide 21: IQOS Consumer Journey
IQOS Consumer Journey Conversion Purchase Trial Engagement Awareness For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 21
Slide 22: IQOS Consumer Journey - Awareness
IQOS Consumer Journey - Awareness Adult Smoker Awareness 40% 31% IQOS Marlboro 2H 2019 - Atlanta Smooth Ice 1H 2019 - National Source: ALCS CMI Estimates All-third party trademarks remain the property of their respective owners. For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 22
Slide 23: IQOS Retail Ecosystem
IQOS Retail Ecosystem Kiosks Boutiques Mobile Pop-Up HeatSticks® Experts Pods Corners Retailers All-third party trademarks remain the property of their respective owners. For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 23
Slide 24: IQOS Consumer Journey – Engagement, Trial & Purchase
IQOS Consumer Journey – Engagement, Trial & Purchase ~55% ~60% Conversion Purchase Trial Engagement Awareness Source: GMR Queue Extract through 02/01/2020, GMR Sales Extract through 02/01/2020 For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 24
Slide 25: IQOS Purchaser Consumer Profile
IQOS Purchaser Consumer Profile Atlanta Lead Market Age Gender 5% 29% 43% 31% 71% 21% 21-29 40-59 Male Female 30-39 60+ Source: GMR Queue Extract through 02/01/2020, GMR Sales Extract through 02/01/2020 For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 25
Slide 26: IQOS Purchaser Profile
IQOS Purchaser Profile Cigarette Brand by Engagement Channel – Atlanta Lead Market 17% 18% 19% 5% 9% 10% 32% 48% 7% 4% 6%4%7% 8% 3% 28% 61% 72% 65% 62% 37% 38% 15% 7% Boutiques Corners/Pods/MRU Experts Marlboro Newport Camel NAS Other Source: GMR Queue Extract through 02/01/2020, GMR Sales Extract t
Slide 27: Charlotte, NC IQOS Expansion
Charlotte, NC IQOS Expansion All-third party trademarks remain the property of their respective owners. For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 27
Slide 28: IQOS 3 Submission
IQOS 3 Submission PMI plans to submit a supplemental PMTA for the IQOS 3 device The IQOS 3 device has a shorter battery charge time versus the currently authorized 2.4 device All-third party trademarks remain the property of their respective owners. For Investor Presentation ONLY | CAGNY 2020 |
Slide 29: on! Manufacturing – Richmond, VA
on! Manufacturing – Richmond, VA Our Richmond Manufacturing Center is a state-of-the-art, FDA-compliant facility that’s a key competitive advantage to our success as an enterprise We expect to have annualized capacity of 50 million cans by mid-year and 75 million cans by the end of the year For
Slide 30: on! Packaging & Portfolio
on! Packaging & Portfolio All Seven Flavors Available in Five Nicotine Strengths For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 30
Slide 31: on! Actual Use Study – Behavioral Switch
on! Actual Use Study – Behavioral Switch: Cigarettes/Smokeless to on! 72% 28% Adult Smokers Adult Dippers n= 399 n=353 (Base: Completed Phase 2); Users had expressed interest in on! after brief trial period. Phase 2 Study participants were provided on! in various nicotine levels and flavor varieties
Slide 32: Adult Tobacco Consumer Basket Analysis
Adult Tobacco Consumer Basket Analysis Tobacco Basket Volume Composition in Four Weeks Prior to First on! or Zyn Purchase on! Zyn 3% 16% 16% 34% 58% 50% 39% Cigarettes MST & Snus Nicotine Pouches Source: POS Scan data April – December 2019 (Top 5 Convenience Chain By Smokeless Volume) For Investor P
Slide 33: Percent Reduction in HPHC levels of on! 4 mg Mint
Percent Reduction in HPHC levels of on! 4 mg Mint Product Compared to General® Snus in Market 100% >83% >97% >99% >97% 80% 60% 40% 20% Not Detectable 0% NNK NNN B(a)P Arsenic* Cadmium* Acetaldehyde* Formaldehyde *Arsenic and Cadmium were below the limit of quantification (BLOQ) in on! products. The
Slide 34: Our World-Class Sales Organization
Our World-Class Sales Organization A leading sales force of over 1,600 employees For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 34
Slide 35: Altria's Enhanced Business Platform
Altria’s Enhanced Business Platform Combustible Noncombustible Tobacco Complementary Tobacco Portfolio Brands & Investments Assets Marlboro Copenhagen Leading Leading MST brand cigarette brand Top 10 domestic wine producer Black & Mild IQOS Leading Global heated tobacco tipped cigar brand leader (U.
Slide 36: Key Macro-Economic Indicators
Key Macro-Economic Indicators Unemployment Rate Total Consumer Confidence Housing Starts (in millions) 10% 180 2 130 128 120 1.3 1.2 1.2 1.2 5.3% 4.9% 98 100 1.1 4.4% 3.9% 3.7% 0% 0 0 2015 2017 2019 2015 2017 2019 2015 2017 2019 Source: US. Department of Labor, Bureau of Labor Statistics & The Confe
Slide 37: Consistent Cigarette Prevalence Trends
Consistent Cigarette Prevalence Trends Adult Smoker Prevalence - Past 30 day, 12 month moving 25% 10% Jun-14 Jun-15 Jun-16 Jun-17 Jun-18 Jun-19 Source: Age 21+, P30D ATCT Jul 2013 to Dec 2019` For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 37
Slide 38: Estimated Adjusted Cigarette Industry Volume Decline Rates
Estimated Adjusted Cigarette Industry Volume Decline Rates Annual Quarterly FY 2018 FY 2019 Q1 2019 Q2 2019 Q3 2019 Q4 2019 (4.5%) (4.5%) (4.5%) (5.5%) (5.5%) (6.0%) Source: Altria Company Reports For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 38
Slide 39: Cigarette Industry Volume Decomposition Estimates
Cigarette Industry Volume Decomposition Estimates 2017 2018 2019 -2.5% -2.5% -2.5% For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | -1.3% -1.1% -1.2% -0.2% -0.5% -0.4% (4.0%) 1 -2.0% (4.5%) (5.5%) 2 Secular Decline 3 Cigarette Price Elasticity Macroeconomic & Other Factors Additional Cross
Slide 40: Total Cigarette Industry Effective Pack Price
Total Cigarette Industry Effective Pack Price Estimated % Change vs. Prior Year FET 15% 10% CA SET 5% 0% 2001 2003 2005 2007 2009* 2011 2013 2015 2017 2019 Note: Estimates are subject to revision based on restatements Sources: ALCS CMI Estimates; SymphonyIRI Group/Capstone; IRI Unify *2009 not shown
Slide 41: Premium and Discount Cigarette Categories – Annual Retail Share
Premium and Discount Cigarette Categories – Annual Retail Share Deep Discount Branded Discount Premium 100 75.9 75.8 24.1 24.2 0 2001 2003 2005 2007 2009 2011 2013 2015 2017 2019 Sources: ALCS CMI Estimates; SymphonyIRI Group/Capstone; IRI Unify Note: Estimates are subject to revision based on resta
Slide 42: Exceptional 2019 Core Tobacco Business Performance
Exceptional 2019 Core Tobacco Business Performance For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 42
Slide 43: Smokeable Products Segment Financial Performance
Smokeable Products Segment Financial Performance Adjusted OCI (in millions)* Adjusted OCI Margins* 8.6% +3.9pp $9,173 $8,449 54.5% 50.6% 2018 2019 2018 2019 Source: Altria company reports * For reconciliations of non-GAAP to GAAP measures visit Altria.com. Note: Reported annualized dividend per shar
Slide 44: Marlboro Share Stability
Marlboro Share Stability 43.2 43.2 43.1 Q4 2017 FY 2018 FY 2019 IRI/MSAi Info Scan Cigarette 2019-Blended, as of 12/29/19 For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 44
Slide 45: Marlboro Bold Ice
Marlboro Bold Ice For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 45
Slide 46: Marlboro Rewards
Marlboro Rewards Over 2.5 million adult smokers enrolled; 200 million pack codes entered For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 46
Slide 47: PM USA Discount Portfolio
PM USA Discount Portfolio For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 47
Slide 48: Smokeless Products Segment Financial Performance
Smokeless Products Segment Financial Performance Adjusted OCI ($ in millions)* Adjusted OCI Margins* +9.7% +3.0pp $1,606 68.7% 71.7% $1,464 2018 2019 2018 2019 Source: Altria company reports * For reconciliations of non-GAAP to GAAP measures visit Altria.com. For Investor Presentation ONLY | CAGNY 2
Slide 49: Copenhagen
Copenhagen Adult Dippers describe Copenhagen Packs as “the perfect mix between long cut and a pouch” Source: CMI Consumer Research (January 2019) For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 49
Slide 50: Oral Tobacco Products Financial Reporting Segment
Oral Tobacco Products Financial Reporting Segment Beginning Q1 2020, we expect to rename the “smokeless products” financial reporting segment to the “oral tobacco products” segment Our oral tobacco product segment will include financial results, volume and retail share performance from our MST a
Slide 51: Continued Constructive Engagement with FDA
Continued Constructive Engagement with FDA 274 Total Substantial Equivalence Market Orders Received For Cigarettes & Smokeless Products 164 86 24 2011 - 2017 2018 2019 For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 51
Slide 52: Substantial Equivalence (SE) Process For Cigars
Substantial Equivalence (SE) Process For Cigars % of Volume With We are pursuing regulatory clearance for our Pre-Market Authorization* cigar portfolio through the SE process We believe Middleton is the best positioned >80% cigar manufacturer to navigate the FDA framework Middleton has been pr
Slide 53: Complementary Alcohol Assets
Complementary Alcohol Assets Note: Third party trademarks are the property of their respective owners and are included for informational purposes only. For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 53
Slide 54: Opportunity for Cronos in the Cannabis Industry
We remain very excited about the opportunity for Cronos to position itself for future leadership within the cannabis industry In the U.S., we support federal legalization of cannabis under an appropriate regulatory framework We intend to work with policy makers and regulators to establish a re
Slide 55: Committed to a Strong Balance Sheet and Balanced Capital Allocation
Committed to a Strong Balance Sheet and Balanced Capital Allocation Credit Metrics as of Committed to maintaining an investment grade December 31, 2019 credit rating 4.2% Committed to an 80% dividend payout ratio target 2.3x 2019 marked our 54th dividend increase in the past 50 years We’ve g
Slide 56: 2020 Adjusted Diluted EPS Guidance
2020 Adjusted Diluted EPS Guidance We reaffirm our full-year 2020 adjusted diluted EPS* guidance of $4.39 to $4.51. This range represents a growth rate of 4% to 7% from a 2019 adjusted diluted base of $4.22*. * For reconciliation of non-GAAP to GAAP measures visit altria.com For Investor Presentatio
Slide 57: For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 57
For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 57
Slide 58: Altria Stock Forward Price to Earnings Multiple
Altria Stock Forward Price to Earnings Multiple 25 20.3 10.7 8.4 5 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Jan 2020 NYSE: MO 2009 – 2019 calculated using the end-of-year stock price divided by the next twelve months consensus estimate for adjusted diluted earnings per share Jan 2
Slide 59: All-third party trademarks remain the property of their respective owners.
All-third party trademarks remain the property of their respective owners. For Investor Presentation ONLY | CAGNY 2020 | 02.19.2020 | 59
Altria Group — Consumer Analyst Group of New York (CAGNY) Conference 2020 on 6ix